Published in J Biol Chem on May 07, 2004
Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects. J Biol Chem (2009) 2.27
Protein tyrosine phosphatase function: the substrate perspective. Biochem J (2007) 2.17
Recruitment of the major vault protein by InlK: a Listeria monocytogenes strategy to avoid autophagy. PLoS Pathog (2011) 2.09
Host resistance to lung infection mediated by major vault protein in epithelial cells. Science (2007) 1.30
The vault exterior shell is a dynamic structure that allows incorporation of vault-associated proteins into its interior. Biochemistry (2006) 1.22
Proteomic analysis of blastema formation in regenerating axolotl limbs. BMC Biol (2009) 1.16
Substrate specificity of protein tyrosine phosphatases 1B, RPTPα, SHP-1, and SHP-2. Biochemistry (2011) 1.13
Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev (2013) 1.10
Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study. Mol Cell Proteomics (2013) 1.09
Draft crystal structure of the vault shell at 9-A resolution. PLoS Biol (2007) 1.05
Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J Biol Chem (2009) 1.04
Third target of rapamycin complex negatively regulates development of quiescence in Trypanosoma brucei. Proc Natl Acad Sci U S A (2012) 1.03
The tyrosine phosphatase SHP2 regulates recovery of endothelial adherens junctions through control of β-catenin phosphorylation. Mol Biol Cell (2012) 0.94
Inhibition of interferon response by cystatin B: implication in HIV replication of macrophage reservoirs. J Neurovirol (2011) 0.94
A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer. Biochem Biophys Res Commun (2006) 0.91
Quantifying oncogenic phosphotyrosine signaling networks through systems biology. Curr Opin Genet Dev (2010) 0.91
Transient Blockade of ERK Phosphorylation in the Critical Period Causes Autistic Phenotypes as an Adult in Mice. Sci Rep (2015) 0.90
Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis. Oncotarget (2013) 0.90
MVP and vaults: a role in the radiation response. Radiat Oncol (2011) 0.89
The p80 homology region of TEP1 is sufficient for its association with the telomerase and vault RNAs, and the vault particle. Nucleic Acids Res (2005) 0.89
Major vault protein regulates class A scavenger receptor-mediated tumor necrosis factor-α synthesis and apoptosis in macrophages. J Biol Chem (2013) 0.85
The mechanism of vault opening from the high resolution structure of the N-terminal repeats of MVP. EMBO J (2009) 0.83
Analysis of protein tyrosine phosphatases and substrates. Curr Protoc Mol Biol (2010) 0.83
Structural studies of large nucleoprotein particles, vaults. Proc Jpn Acad Ser B Phys Biol Sci (2012) 0.82
Major vault protein is expressed along the nucleus-neurite axis and associates with mRNAs in cortical neurons. Cereb Cortex (2008) 0.82
Proteomic approaches to understanding the role of the cytoskeleton in host-defense mechanisms. Expert Rev Proteomics (2011) 0.81
Identification and saturable nature of signaling pathways induced by metreleptin in humans: comparative evaluation of in vivo, ex vivo, and in vitro administration. Diabetes (2014) 0.78
14-3-3ε boosts bleomycin-induced DNA damage response by inhibiting the drug-resistant activity of MVP. J Proteome Res (2013) 0.78
PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. Int J Oncol (2012) 0.78
Activation of the NLRP3 inflammasome by vault nanoparticles expressing a chlamydial epitope. Vaccine (2014) 0.78
MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nat Commun (2017) 0.78
Sea urchin vault structure, composition, and differential localization during development. BMC Dev Biol (2005) 0.77
Mining the function of protein tyrosine phosphatases in health and disease. Semin Cell Dev Biol (2014) 0.77
Resolvin D1 via prevention of ROS-mediated SHP2 inactivation protects endothelial adherens junction integrity and barrier function. Redox Biol (2017) 0.75
2-DE Mapping of the Blue Mussel Gill Proteome: The Usual Suspects Revisited. Proteomes (2015) 0.75
Cellular biochemistry methods for investigating protein tyrosine phosphatases. Antioxid Redox Signal (2014) 0.75
Identification of new FGF1 binding partners-Implications for its intracellular function. IUBMB Life (2016) 0.75
Cell-surface major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in hepatocellular carcinomas. Sci Rep (2017) 0.75
The Immune Signaling Adaptor LAT Contributes to the Neuroanatomical Phenotype of 16p11.2 BP2-BP3 CNVs. Am J Hum Genet (2017) 0.75
Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A (2006) 3.74
The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell (2013) 3.27
Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med (2011) 3.09
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A (2008) 3.08
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Protein tyrosine phosphatase function: the substrate perspective. Biochem J (2007) 2.17
Recruitment of the major vault protein by InlK: a Listeria monocytogenes strategy to avoid autophagy. PLoS Pathog (2011) 2.09
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood (2004) 2.08
MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J (2009) 2.06
Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest (2004) 2.00
MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation. Int J Legal Med (2010) 1.78
Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab (2006) 1.76
The MAP kinase phosphatase MKP-1 regulates BDNF-induced axon branching. Nat Neurosci (2010) 1.74
Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J Biol Chem (2005) 1.74
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res (2010) 1.69
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res (2003) 1.67
Epidermal growth factor-mediated activation of the ETS domain transcription factor Elk-1 requires nuclear calcium. J Biol Chem (2002) 1.53
SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Mol Cell Biol (2004) 1.53
c-Met must translocate to the nucleus to initiate calcium signals. J Biol Chem (2007) 1.52
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther (2005) 1.49
MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol (2010) 1.49
O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1α stability. Cell Metab (2012) 1.46
Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene (2003) 1.39
Nucleoplasmic calcium is required for cell proliferation. J Biol Chem (2007) 1.34
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther (2005) 1.34
Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes (2005) 1.33
Host resistance to lung infection mediated by major vault protein in epithelial cells. Science (2007) 1.30
SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis. J Cell Physiol (2004) 1.21
Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat (2011) 1.20
A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor. J Biol Chem (2008) 1.20
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res (2013) 1.14
The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation. Mol Cell Biol (2005) 1.14
Major vault protein, in concert with constitutively photomorphogenic 1, negatively regulates c-Jun-mediated activator protein 1 transcription in mammalian cells. Cancer Res (2005) 1.12
SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. J Cell Biol (2006) 1.10
Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res (2002) 1.08
Role of MKP-1 in osteoclasts and bone homeostasis. Am J Pathol (2009) 1.07
Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res (2010) 1.06
Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions. Cell Mol Life Sci (2012) 1.03
Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Res Treat (2013) 1.02
Structural domains of vault proteins: a role for the coiled coil domain in vault assembly. Biochem Biophys Res Commun (2002) 1.02
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. Proc Natl Acad Sci U S A (2006) 1.01
MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in mice. J Clin Invest (2009) 1.01
Physiological signaling specificity by protein tyrosine phosphatases. Physiology (Bethesda) (2009) 1.01
Role of SHP-2 in fibroblast growth factor receptor-mediated suppression of myogenesis in C2C12 myoblasts. Mol Cell Biol (2002) 0.99
MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. Int J Cancer (2014) 0.98
Up-regulation of drug resistance-related vaults during dendritic cell development. J Immunol (2002) 0.96
Loss of mitogen-activated protein kinase phosphatase-1 protects from hepatic steatosis by repression of cell death-inducing DNA fragmentation factor A (DFFA)-like effector C (CIDEC)/fat-specific protein 27. J Biol Chem (2011) 0.96
MAP kinase phosphatase-1 deficiency impairs skeletal muscle regeneration and exacerbates muscular dystrophy. FASEB J (2010) 0.96
The tyrosine phosphatase SHP2 regulates recovery of endothelial adherens junctions through control of β-catenin phosphorylation. Mol Biol Cell (2012) 0.94
Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation. J Biol Chem (2008) 0.93
Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal (2009) 0.91
Calcium signaling in the nucleus. Can J Physiol Pharmacol (2006) 0.90
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin Cancer Res (2012) 0.90
Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5. J Clin Invest (2013) 0.89
Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat (2013) 0.89
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther (2006) 0.88
MAP kinase phosphatase-1--a new player at the nexus between sarcopenia and metabolic disease. Aging (Albany NY) (2010) 0.88
JAK2 and SHP2 reciprocally regulate tyrosine phosphorylation and stability of proapoptotic protein ASK1. J Biol Chem (2009) 0.87
Novel role for SHP-2 in nutrient-responsive control of S6 kinase 1 signaling. Mol Cell Biol (2012) 0.86
Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration. Mol Cell Biol (2013) 0.86
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res (2013) 0.86
Mitogen-activated protein kinase phosphatase-1 - a potential therapeutic target in metabolic disease. Expert Opin Ther Targets (2010) 0.85
Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. J Pharm Biomed Anal (2011) 0.85
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur J Cancer (2010) 0.84
Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope. Exp Cell Res (2005) 0.84
Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding. J Pharm Biomed Anal (2011) 0.84
The formation of vault-tubes: a dynamic interaction between vaults and vault PARP. J Cell Sci (2003) 0.83
Analysis of protein tyrosine phosphatases and substrates. Curr Protoc Mol Biol (2010) 0.83
Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression. Cancer Res (2004) 0.83
Gene expression profiling of histiocytic sarcomas in a canine model: the predisposed flatcoated retriever dog. PLoS One (2013) 0.83
SHP-2 regulates cell growth by controlling the mTOR/S6 kinase 1 pathway. J Biol Chem (2007) 0.83
Unimpaired dendritic cell functions in MVP/LRP knockout mice. Immunology (2003) 0.82
The relevance of microdialysis for clinical on:cology. Curr Clin Pharmacol (2006) 0.82
Evaluation of patient enrollment in oncology phase I clinical trials. Oncologist (2013) 0.81
The genomic sequence of the murine major vault protein and its promoter. Gene (2002) 0.81
Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib? Blood (2013) 0.80
The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin. Eur J Cancer (2012) 0.80
Stressed tumor cell, chemosensitized cancer. Nat Med (2011) 0.80
Incident cancer risk after the start of aspirin use: results from a Dutch population-based cohort study of low dose aspirin users. Int J Cancer (2013) 0.79
Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal (2010) 0.79
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin Cancer Res (2013) 0.78
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients. Cancer Chemother Pharmacol (2008) 0.78
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal (2009) 0.78
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. Cancer Chemother Pharmacol (2010) 0.77
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study. Eur J Cancer (2011) 0.76
The issue of non-specific binding of cabazitaxel. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.76
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res Treat (2015) 0.76
Effects of methimazole on the elimination of irinotecan. Cancer Chemother Pharmacol (2010) 0.75
miRNAs and cancer. J RNAi Gene Silencing (2006) 0.75
Identification of receptor protein tyrosine phosphatases (RPTPs) as regulators of receptor tyrosine kinases (RTKs) using an RPTP siRNA-RTK substrate screen. Methods Mol Biol (2015) 0.75
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence. Clin Pharmacokinet (2015) 0.75